Review



10ul hrma reaction  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Bio-Rad 10ul hrma reaction
    Development of a Zebrafish CRISPR/Cas9 pipeline to assess functional impact of DMD modifier candidates . (A) Adult fish heterozygous for dmd are intercrossed to generate embryos for the screen. Because DMD in zebrafish follows an autosomal recessive inheritance pattern, one-quarter of the intercross progeny are homozygous dmd mutants ( dmd-/- ), all of which are identifiable using birefringence imaging by 4 dpf due to the presence of muscle lesions. Homozygous wild-type ( dmd+/+ ) and heterozygous dmd ( dmd+/- ) fish are indistinguishable. Embryos are injected by the 1-cell stage with modifier-targeting CRISPR and Cas9 protein or raised as uninjected controls. All fish are assayed for DMD onset between 2-4 dpf using live birefringence imaging. At 4 dpf, all fish are fixed, birefringence imaged, and genotyped via <t>HRMA.</t> (B, B’) Representative examples of wild-type (WT, top) and dmd-/- mutant (bottom) fish imaged via birefringence at 4 dpf. The boxes in B are shown magnified in B’. Wild-type fish show strong, uniform birefringence, whereas dmd mutant fish have variably-sized non-birefringence patches indicating dystrophic lesions (white arrows). Fish containing one or more lesion, regardless of lesion size or number, are scored as dystrophic in the onset assay.
    10ul Hrma Reaction, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 204 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/10ul hrma reaction/product/Bio-Rad
    Average 99 stars, based on 204 article reviews
    10ul hrma reaction - by Bioz Stars, 2026-04
    99/100 stars

    Images

    1) Product Images from "Validation of Duchenne muscular dystrophy candidate modifiers using a CRISPR-Cas9-based approach in zebrafish"

    Article Title: Validation of Duchenne muscular dystrophy candidate modifiers using a CRISPR-Cas9-based approach in zebrafish

    Journal: bioRxiv

    doi: 10.1101/2025.05.20.655139

    Development of a Zebrafish CRISPR/Cas9 pipeline to assess functional impact of DMD modifier candidates . (A) Adult fish heterozygous for dmd are intercrossed to generate embryos for the screen. Because DMD in zebrafish follows an autosomal recessive inheritance pattern, one-quarter of the intercross progeny are homozygous dmd mutants ( dmd-/- ), all of which are identifiable using birefringence imaging by 4 dpf due to the presence of muscle lesions. Homozygous wild-type ( dmd+/+ ) and heterozygous dmd ( dmd+/- ) fish are indistinguishable. Embryos are injected by the 1-cell stage with modifier-targeting CRISPR and Cas9 protein or raised as uninjected controls. All fish are assayed for DMD onset between 2-4 dpf using live birefringence imaging. At 4 dpf, all fish are fixed, birefringence imaged, and genotyped via HRMA. (B, B’) Representative examples of wild-type (WT, top) and dmd-/- mutant (bottom) fish imaged via birefringence at 4 dpf. The boxes in B are shown magnified in B’. Wild-type fish show strong, uniform birefringence, whereas dmd mutant fish have variably-sized non-birefringence patches indicating dystrophic lesions (white arrows). Fish containing one or more lesion, regardless of lesion size or number, are scored as dystrophic in the onset assay.
    Figure Legend Snippet: Development of a Zebrafish CRISPR/Cas9 pipeline to assess functional impact of DMD modifier candidates . (A) Adult fish heterozygous for dmd are intercrossed to generate embryos for the screen. Because DMD in zebrafish follows an autosomal recessive inheritance pattern, one-quarter of the intercross progeny are homozygous dmd mutants ( dmd-/- ), all of which are identifiable using birefringence imaging by 4 dpf due to the presence of muscle lesions. Homozygous wild-type ( dmd+/+ ) and heterozygous dmd ( dmd+/- ) fish are indistinguishable. Embryos are injected by the 1-cell stage with modifier-targeting CRISPR and Cas9 protein or raised as uninjected controls. All fish are assayed for DMD onset between 2-4 dpf using live birefringence imaging. At 4 dpf, all fish are fixed, birefringence imaged, and genotyped via HRMA. (B, B’) Representative examples of wild-type (WT, top) and dmd-/- mutant (bottom) fish imaged via birefringence at 4 dpf. The boxes in B are shown magnified in B’. Wild-type fish show strong, uniform birefringence, whereas dmd mutant fish have variably-sized non-birefringence patches indicating dystrophic lesions (white arrows). Fish containing one or more lesion, regardless of lesion size or number, are scored as dystrophic in the onset assay.

    Techniques Used: CRISPR, Functional Assay, Imaging, Injection, Mutagenesis



    Similar Products

    10ul hrma reaction  (Bio-Rad)
    99
    Bio-Rad 10ul hrma reaction
    Development of a Zebrafish CRISPR/Cas9 pipeline to assess functional impact of DMD modifier candidates . (A) Adult fish heterozygous for dmd are intercrossed to generate embryos for the screen. Because DMD in zebrafish follows an autosomal recessive inheritance pattern, one-quarter of the intercross progeny are homozygous dmd mutants ( dmd-/- ), all of which are identifiable using birefringence imaging by 4 dpf due to the presence of muscle lesions. Homozygous wild-type ( dmd+/+ ) and heterozygous dmd ( dmd+/- ) fish are indistinguishable. Embryos are injected by the 1-cell stage with modifier-targeting CRISPR and Cas9 protein or raised as uninjected controls. All fish are assayed for DMD onset between 2-4 dpf using live birefringence imaging. At 4 dpf, all fish are fixed, birefringence imaged, and genotyped via <t>HRMA.</t> (B, B’) Representative examples of wild-type (WT, top) and dmd-/- mutant (bottom) fish imaged via birefringence at 4 dpf. The boxes in B are shown magnified in B’. Wild-type fish show strong, uniform birefringence, whereas dmd mutant fish have variably-sized non-birefringence patches indicating dystrophic lesions (white arrows). Fish containing one or more lesion, regardless of lesion size or number, are scored as dystrophic in the onset assay.
    10ul Hrma Reaction, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/10ul hrma reaction/product/Bio-Rad
    Average 99 stars, based on 1 article reviews
    10ul hrma reaction - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Development of a Zebrafish CRISPR/Cas9 pipeline to assess functional impact of DMD modifier candidates . (A) Adult fish heterozygous for dmd are intercrossed to generate embryos for the screen. Because DMD in zebrafish follows an autosomal recessive inheritance pattern, one-quarter of the intercross progeny are homozygous dmd mutants ( dmd-/- ), all of which are identifiable using birefringence imaging by 4 dpf due to the presence of muscle lesions. Homozygous wild-type ( dmd+/+ ) and heterozygous dmd ( dmd+/- ) fish are indistinguishable. Embryos are injected by the 1-cell stage with modifier-targeting CRISPR and Cas9 protein or raised as uninjected controls. All fish are assayed for DMD onset between 2-4 dpf using live birefringence imaging. At 4 dpf, all fish are fixed, birefringence imaged, and genotyped via HRMA. (B, B’) Representative examples of wild-type (WT, top) and dmd-/- mutant (bottom) fish imaged via birefringence at 4 dpf. The boxes in B are shown magnified in B’. Wild-type fish show strong, uniform birefringence, whereas dmd mutant fish have variably-sized non-birefringence patches indicating dystrophic lesions (white arrows). Fish containing one or more lesion, regardless of lesion size or number, are scored as dystrophic in the onset assay.

    Journal: bioRxiv

    Article Title: Validation of Duchenne muscular dystrophy candidate modifiers using a CRISPR-Cas9-based approach in zebrafish

    doi: 10.1101/2025.05.20.655139

    Figure Lengend Snippet: Development of a Zebrafish CRISPR/Cas9 pipeline to assess functional impact of DMD modifier candidates . (A) Adult fish heterozygous for dmd are intercrossed to generate embryos for the screen. Because DMD in zebrafish follows an autosomal recessive inheritance pattern, one-quarter of the intercross progeny are homozygous dmd mutants ( dmd-/- ), all of which are identifiable using birefringence imaging by 4 dpf due to the presence of muscle lesions. Homozygous wild-type ( dmd+/+ ) and heterozygous dmd ( dmd+/- ) fish are indistinguishable. Embryos are injected by the 1-cell stage with modifier-targeting CRISPR and Cas9 protein or raised as uninjected controls. All fish are assayed for DMD onset between 2-4 dpf using live birefringence imaging. At 4 dpf, all fish are fixed, birefringence imaged, and genotyped via HRMA. (B, B’) Representative examples of wild-type (WT, top) and dmd-/- mutant (bottom) fish imaged via birefringence at 4 dpf. The boxes in B are shown magnified in B’. Wild-type fish show strong, uniform birefringence, whereas dmd mutant fish have variably-sized non-birefringence patches indicating dystrophic lesions (white arrows). Fish containing one or more lesion, regardless of lesion size or number, are scored as dystrophic in the onset assay.

    Article Snippet: DNA was extracted from adult fin tissue or whole larvae as described above and 1ul was used as template in a 10ul HRMA reaction (BioRad 172-5112) in a CFX Duet Real-Time PCR System (#12016265) and analyzed using BioRad Precision Melt Analysis Software.

    Techniques: CRISPR, Functional Assay, Imaging, Injection, Mutagenesis